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Objectives: Regorafenib is indicated in the treatment of locally advanced, non-
resectable gastrointestinal stromal tumors (GIST) that did not respond to prior 
imatinib mesylate and sunitinib malate. The objective of this study is to evaluate 
the cost-effectiveness of regorafenib compared to standard care, since no other third 
line treatment is available, in metastatic/inoperable GISTs in Turkey. MethOds: A 
Markov model taking transitions of patients between three health states of “progres-
sion-free”, “progressed” or “dead” was adapted to Turkish settings. Clinical transition 
inputs between health states and safety data were mainly derived from GRID study. 
Economic inputs were based on the experts’ opinion addressing local treatments, 
routine monitoring and adverse event management algorithms. The incremental 
cost-effectiveness ratios (ICER) were calculated per quality adjusted life years (QALY) 
gained. Analyses were conducted from the Turkish Payer Social Security Institution 
perspective. All costs were calculated in Turkish Liras (TL). The cost effectiveness 
(CE) threshold defined by World Health Organization (WHO) for developing countries 
as ICER 1-3 fold of annual income per capita was calculated based on the Turkish 
2014 annual income per capita of 10,404.00 USD and converted to TL using TL/USD 
currency rate of 2.28 (end of 2014). Results: Total costs associated with regorafenib 
and standard care are 22,902 and 1,692 TL, respectively. On the other hand, QALYs 
gained with regorafenib (2.714) was almost twice compared to standard care (1.402), 
with an ICER of 16,481 TL/year. This additional cost of treatment is below the lower 
margin of CE threshold that was 23,721.00 TL. cOnclusiOns: Regorafenib is a cost-
effective treatment option in metastatic/inoperable GISTs in Turkey. Compared to 
standard care, the additional cost of treatment is below the CE threshold.
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Objectives: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that has 
demonstrated its efficacy in treating Gastrointestinal stromal tumor (GIST) patients 
who are no longer responded to imatinib 400mg/day. The purpose of this study is to 
evaluate the cost-effectiveness of sunitinib as a second-line treatment in patients 
with advanced GISTs in China from a third party payer’s perspective. MethOds: 
A Markov model was developed to simulate disease progression and to determine 
cost and effectiveness outcomes over a 5-year time horizon. The different second-
line treatment arms compared were sunitinib 50 mg/day (4 weeks on and 2 weeks 
off), imatinib 600 mg/day, imatinib 800 mg/day, and best supportive care (BSC). The 
probabilities of state transitions and utilities were obtained from previous published 
trials. Resource use and costs data were obtained from previous studies and public 
sources. A 3.5% annual discount rate after the first year was applied to both costs 
and outcomes. The incremental cost-effectiveness ratios (ICER) between treatment 
with sunitinib vs. other treatment options were calculated. Results: In the base 
case, treatment with sunitinib vs. imatinib 600 mg resulted in 0.744 PFLY gained, 
0.423 LY gained and 0.398 QALYs gained at an incremental cost of RMB14,750. The 
ICER was RMB37,023 per QALY gained. Treatment with sunitinib was dominant 
compared with imatinib 800 mg, with lower costs and higher QALYs . Treatment 
with sunitinib vs BSC resulted in patients’ benefits of 0.257 PFLY gained, 1.357 LY 
gained and 0.836 QALYs gained at an incremental cost of RMB106,889. The ICER 
was RMB127,801 per QALY gained. cOnclusiOns: Among patients with advanced 
GISTs who have failed imatinib 400mg/day as the first-line treatment, sunitinib 
provides greater clinical benefit than high-dose imatinib or BSC. In the Chinese 
setting, sunitinib is estimated to be either cost-saving or cost-effective compared 
with imatinib 800 mg, imatinib 600mg or BSC.
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Objectives: To assess the cost-effectiveness of ceritinib versus other therapies in 
the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung 
cancer (NSCLC) from the UK National Health Service (NHS) and Personal Social 
Service (PSS) perspective. MethOds: A partitioned survival model with three health 
states (progression-free, progressive, and death) was developed to compare ceri-
tinib versus other treatments in patients with ALK+ NSCLC who were previously 
treated with chemotherapy (post-CT), or with an ALK inhibitor, regardless of prior 
chemotherapy (post-ALKi). The comparator arms included crizotinib, docetaxel, and 
pemetrexed in the post-CT population and best supportive care (BSC), docetaxel, 
and pemetrexed in the post-ALKi population. Progression-free survival and overall 
survival for ceritinib were estimated using the ASCEND-1 (NCT01283516), ASCEND-2 
(NCT01685060), and ASCEND-3 (NCT01685138) trial data. Parametric models were 
used to extrapolate outcomes beyond the trial period. Survival data for compara-
tors were obtained from published clinical trials. Drug acquisition, administration, 
medical and adverse event (AE) costs were obtained from publicly available data-
bases. Utilities for health states and disutilities for AEs based on EQ-5D were derived 
from literature. Incremental costs per quality-adjusted life year (QALY) gained were 
estimated comparing ceritinib vs. each comparator. Univariate and probabilistic 
sensitivity analyses were performed. Results: Over 10 years, ceritinib was associ-
ated with 2.69 QALYs and total direct costs of £80,445 for post-CT population. The 
incremental cost per QALY was £30,536 comparing ceritinib vs. crizotinib, £44,847 vs. 
docetaxel, and £38,966 vs. pemetrexed. Among post-ALKi population, the QALY and 
total direct costs for ceritinib were 0.94 and £45,712 respectively. The incremental 
cost per QALY was £48,808 comparing ceritinib vs. BSC, £57,660 vs. docetaxel, and 
£40,145 vs. pemetrexed. Sensitivity analysis results were consistent with the base-
case findings. cOnclusiOns: Based on the willingness-to-pay threshold for end-
(iii) best supportive care (BSC). To compare I+R to steroids with rituximab (an 
alternative treatment for the patient group in Study 116) and to make exploratory 
comparisons to chemo-immunotherapies, curve fits to systematically-identified 
comparator trial data were made using a common-shape approach and adjust-
ment for prognostic factors. Utility data and drug, medical resource, adverse event 
and terminal care costs were obtained from Study 116 EQ-5D surveys, published 
sources and clinical input. Results: Compared to (i) rituximab monotherapy, (ii) 
ofatumumab monotherapy and (iii) BSC, in patients ineligible for chemo-immu-
notherapy, the base case ICERs for I+R were (i) £21,224, (ii) £9,116 and (iii) £28,015 
per QALY gained, respectively and inclusive of a simple price discount. Further 
comparisons provided ICERs ranging from £20,431 to £34,603. cOnclusiOns: 
I+R was shown to be cost effective in previously-treated patients ineligible for 
chemo-immunotherapy.
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Objectives: To evaluate the cost-effectiveness of ofatumumab plus chlorambucil 
(OChl) versus chlorambucil (Chl) for the first-line treatment of chronic lympho-
cytic leukemia (CLL) in patients not eligible for fludarabine-based therapy from the 
United Kingdom health care payer perspective. MethOds: A semi-Markov decision 
model was developed with a lifetime time horizon of 25 years and a 3-month cycle 
length. The COMPLEMENT-1 trial provided estimates of overall response rates (ORR), 
progression-free survival (PFS), overall survival (OS), safety data, and preprogression 
utility weights (EQ-5D). The number of patients in the “preprogression,” “progres-
sive disease,” and “dead” health states at the end of each cycle was determined by 
parametric survival functions for PFS and OS. Long-term predictions for OS were 
guided by external data; the treatment effect observed in the trial was assumed not 
to continue beyond trial follow-up. Data from published literature and UK treatment 
practices and patterns were used to inform costs and utility in the postprogression 
health states. Incremental lifetime costs and quality-adjusted life-years (QALYs) 
were calculated. Results: The base-case incremental cost-effectiveness ratio (ICER) 
was £32,950 per QALY gained, with incremental discounted costs and QALYs of 
£10,492 and 0.32, respectively. Discount rate was 3.5% for both cost and outcomes. 
The probability of cost-effectiveness at a willingness-to-pay threshold of £30,000 
per QALY was 43%. Univariate sensitivity analyses indicated that the proportion of 
patients who received active therapy after progression following first-line treatment 
(responders, active second-line treatment) had the largest influence on the ICER. 
However, none of the variables considered generated an ICER exceeding £38,000 
per QALY gained. cOnclusiOns: The improved ORR, PFS, and OS for OChl com-
pared with Chl translated to improved long-term health outcomes in the base-case 
analysis. The results were robust in a wide range of sensitivity analyses and did not 
exceed £38,000/QALY.
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Objectives: Idelalisib/ rituximab (IR) is licenced for the treatment of adults 
with CLL who either have received at least one previous therapy and as first 
line treatment for patients with del17p/TP53 mutations. Prior to the availability 
of IR, individuals in these patient groups received best supportive care (BSC). 
The clinical efficacy of the IR in these patient groups was demonstrated in a 
Phase III RCT (‘study 116’). The cost-effectiveness of IR in this patient group is 
unknown. MethOds: A response stratified partitioned survival model (overall 
survival - OS, progression free survival - PFS) was developed to estimate the life-
time costs and benefits associated with IR and BSC for a Scottish NHS perspective 
using a lifetime horizon and monthly cycles. OS, PFS, overall response (OR) and 
resource use data was taken directly from study 116. Information from study 
116 was used as far as possible for patients with del17p / TP53 mutations, with 
expert opinion used where necessary. Utility scores were taken from published 
sources. Unit/drug costs were taken from national databases and discounted at 
3.5% p.a. Probabilistic and deterministic sensitivity analyses were conducted to 
estimate the confidence around the results. Outcomes are reported via incremen-
tal cost-effectiveness ratios (ICER, benefit expressed as QALYs). Results: For all 
patients the ICER for all patients was £32,180/ QALY (Δ QALYs:2.04, Δ Costs:£64,629). 
In patients with del 17p/TP53 mutations the ICER was £19,040/QALY (Δ QALYs:4.39, 
Δ Costs:£83,636). The results were sensitive to changes in OR rates and utility val-
ues. In particular, the ICERs fell below £30,000/QALY if utility values from previ-
ous UK HTAs of treatments for CLL were used. The ICERs were robust to changes 
in adverse event rates/costs and alterations to background resource use pat-
terns. cOnclusiOns: IR is likely to be a cost-effective intervention in all CLL 
patients for which it has achieved European marketing approval.
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with filgrastim/lenograstim (0.340, 0.316, 0.410 for TC, AC-T, FEC-D, respectively). 
PP with pegfilgrastim was cost-effective versus SP with pegfilgrastim across all 
chemotherapy schemes (ICERs per FN event avoided: € 7,472, € 18,017 and € 9,996 for 
TC, AC-T and FEC-D, respectively). SP with pegfilgrastim was cost-effective versus 
no prophylaxis. All other treatment strategies were excluded from the analysis via 
extended dominance or were dominated by a less expensive and more effective 
strategy. For instance, PP and SP with lipegfilgrastim was found to be dominated 
by PP and SP with pegfilgrastim.These results held for patients with stage II and III 
BC. cOnclusiOns: Our analysis finds PP with pegfilgrastim to be a cost-effective 
option for chemotherapy-induced FN in patients with BC in Greece.
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Objectives: To evaluate which strategy for implementing exercise interventions for 
cancer survivors and increasing providers´ adherence to the exercise guidance has 
the highest expected value, using value-of-implementation analysis. MethOds: 
The net-benefit framework underpinning health economic evaluations is used to 
conduct a value-of-implementation analysis considering seven implementation 
strategies (ISTs), including continuing medical education (CME), educational out-
reach visits (EOV), educational printed materials (EPM), local opinion leaders (LOPL), 
audit and feedback (AF), reminder systems (RS), and a multifaceted strategy (MF) 
consisting of CME and AF. The analysis consists of four steps; (1) analysing the 
expected value of perfect implementation (EVPIM) (2) assessing the estimated costs 
of the various ISTs, (3) comparing the ISTs´ costs to the EVPIM to decide which of 
these are considered cost-effective, and (4) assessing the total net benefit of the ISTs 
to identify which strategy has the greatest value. Results: The EVPIM for physical 
exercise in the Netherlands is € 522m, which represents the maximum value that 
could be achieved if the guidance was implemented perfectly with a 100% adher-
ence. The costs of the implementation strategies are lowest for PEM with € 710,600 
and highest for MF with € 2,173,700. All ISTs´ costs are well below the EVPIM and thus 
all ISTs are cost-effective. The net-benefit of the ISTs ranges from € 15,753,000 for 
PEM to € 10,150,500 for RS. cOnclusiOns: All evaluated implementation strategies 
are a cost-effective way of implementing physical exercise interventions for cancer 
survivors and increasing health professionals´ adherence to this guideline. However, 
all strategies contribute only marginally to achieving the highest possible value of 
implementation. This suggests that investing in more intensive implementation 
would be justified given the expected net-benefit.
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Objectives: Overall survival (OS) and other important clinical trial endpoints seem 
increasingly more elusive in supporting rapid and efficient incorporation of innova-
tive cancer drugs in clinical practice. We propose a clinical trial based pharmacoeco-
nomic framework to assess the early therapeutic and economic value of ruxolitinib 
in patients with intermediate-2 or high-risk primary myelofibrosis. MethOds: 
Individual level data from patients randomized to ruxolitinib or best available 
therapy (BAT) in the COMFORT-II study was used to estimate: (a) OS, accounting 
for crossover effects, using Rank Preserving Structural Failure Time models; (b) 
treatment benefits beyond normative trial progression endpoints, using treatment 
persistence as a proxy for clinical progression; (c) drug therapy costs considering 
detailed timeline patterns of ruxolitinib dose adjustments, using a piecewise mixed 
regression model for continuous longitudinal data; and (d) the time evolution of the 
average number of red blood cell transfusions per patient, using a mixed regression 
model for ordered multinomial longitudinal data. Results: A 3.3 year increment 
in life expectancy was estimated for ruxolitinib as compared to BAT (HR OS = 0.30; 
[95% CI: 0.17 - 0.55]; p-value < 0.001), resulting in a 2.43 discounted (5%/year) incre-
ment in life years (LY). Corresponding incremental lifetime health care cost amount 
to 97,052€ per patient starting treatment with ruxolitinib. Of those, roughly 90% is 
for drug therapy costs (87,267€ ) with the remaining 9,785€ attributable mainly to 
patients being alive for longer periods and consuming more heath care resources. 
This results in an incremental cost-effectiveness ratio of 40,000€ /LY gained with 
ruxolitinib. A probabilistic sensitivity analysis showed a greater than 95% prob-
ability of ruxolitinib being cost-effective against BAT, at a willingness to pay up 
to 50,000€ /LY. cOnclusiOns: We show how valuable information from clinical 
trials can be used to support informed decisions about the early incorporation of 
innovative drugs.
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Objectives: The objective of this study is to evaluate cost-effectiveness of pertu-
zumab in combination with trastuzumab and docetaxel for HER2-positive metastatic 
breast cancer in Japan. The National Institute for Health and Care Excellence (NICE) in 
the UK did not recommend pertuzumab due to poorer cost-effectiveness. While the 
Ministry of Health and Welfare of Japan decided to cover pertuzumab by health insur-
ance in 2013, its cost-effectiveness in Japan has not yet been reported. MethOds: 
Cost-effectiveness analysis was performed using a Markov model based on clini-
cal data from a phase III randomized double-blind placebo-controlled international 
multicenter clinical trial (CLEOPATRA). Pertuzumab in combination with trastuzumab 
and docetaxel was compared with trastuzumab and docetaxel. The base case was 
of-life cancer drugs, ceritinib may be considered as a cost-effective option compared 
with other available therapies for previous treated ALK+ NSCLC.
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Objectives: To summarize cost-effectiveness of bortezomib (BTZ) for multi-
ple myeloma (MM) and identify bias in the published cost-effectiveness analysis 
(CEA). MethOds: Electronic bibliographic databases were searched from 2003 to 
2014 for eligible CEA. The full publications of included CEAs were reviewed for data 
extraction. The reported base case incremental cost-effectiveness ratio per gained 
quality adjusted life year (QALY) or life year (LY) were converted to the ratio to 2013 
country-specific gross domestic product per capita (GDPPC) to interpret cost-effec-
tiveness according to World Health Organization (WHO) recommendation on cost-
effectiveness threshold (3 GDPPC). The study designs and methods of the included 
CEAs were assessed regarding their impact on cost-effectiveness. Results: 3 CEAs 
reported favourable cost-effectiveness of BTZ as induction treatment prior to stem cell 
transplantation (SCT) in Canada, Poland, and Germany (0.9379 to 2.351 GDPPC/QALY). 
BTZ/melpahlan/prednisone (VMP) was cost-effective compared to MP for MM ineligi-
ble for SCT in Canada, UK, and USA (0.9367 GDPPC to 2.0279 GDPPC/QALY). However, 
the survival outcomes estimated from indirect comparisons for VMP versus thalido-
mide (THD)/MP (MPT) and lenalidomide (LEN)/MP plus LEN as maintenance therapy 
(MPR-R) resulted conflicting cost-effectiveness. For relapsed/refractory MM, BTZ was 
cost-effective in UK (0.9224 to 1.8027GDPPC/LY) and USA (1.1053 or 1.2136 GDPPC/LY) 
when compared to best supportive care. The cost-effectiveness of BTZ for relapsed/
refractory MM was favourable compared to thalidomide in USA (0.5235 GDPPC/LY) 
and dexamethasone (DEX) in Nordic countries. However, the reported conflicting cost-
effectiveness of BTZ relative to LEN/DEX could also result from indirect comparisons 
on survival outcomes. cOnclusiOns: BTZ was cost-effective for MM prior to SCT, 
MM ineligible for SCT, and relapse/refractory MM when compared to conventional 
treatments. However, caution is needed when interpreting the cost-effectiveness 
of BTZ relative to MPT and MPR-R for MM ineligible for SCT or LEN/DEX for relapse/
refractory MM due to the potential bias associated with indirect comparisons.
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Objectives: An economic evaluation was conducted to investigate the Incremental 
Cost-Effectiveness Ratio (ICER) of cetuximab in combination with FOLFIRI versus 
FOLFIRI, between three cohorts of the CRYSTAL study, and determine if the cost- 
effectiveness improves when treatment is stratified to patients with the genetic 
biomarkers, KRAS wild-type and RAS wild-type (wt) MethOds: From the CRYSTAL 
study, Individual Patient Data (IPD) was obtained from Merck Serono Biostatistics 
department. It was categorised into the three cohorts: the Intention To Treat (ITT) 
population and the two subgroups KRAS wild-type and RAS wild-type. Survival 
analysis was conducted on this data using R studio. Adverse events and resec-
tion rates were also obtained for the cohorts. NHS acquisition costs for cetuximab 
were used. A Merck Serono Cost Utility Model was then re-engineered to economi-
cally evaluate the three cohorts for comparison. Results: From this analysis, the 
deterministic base case ICER, cost per Quality Adjusted Life Year (QALY) gained, 
results are £130,929 in the ITT, £72,053 in the KRAS wt and £44,184 in the RAS wt 
cohorts. cOnclusiOns: From these results, it can be concluded that based on the 
data from the CRYSTAL study, stratification of patients by genetic biomarker KRAS 
wt and RAS wt does improve the cost effectiveness of cetuximab plus FOLFIRI versus 
FOLFIRI alone. The RAS wt cohort had the lowest ICER and is therefore the most cost 
effective of the three groups.
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Objectives: To evaluate the cost-effectiveness of primary and secondary proph-
ylaxis (PP & SP) with pegfilgrastim, lipegfilgrastim, and with 6-day filgrastim/
lenograstim for chemotherapy-induced febrile neutropenia (FN) in patients with 
stage II and III breast cancer (BC) in Greece. MethOds: A Markov model containing 
a decision tree was locally adapted to estimate outcomes from payer perspective. 
The analysis was conducted for a lifetime horizon across three different chemo-
therapy schemes (TC, FEC-D and AC-T). Clinical inputs, such as baseline FN risk, 
efficacy of granulocyte colony-stimulating factors (G-CSFs), mortality, effect of FN 
on relative dose intensity were extracted from published studies. Direct medical 
costs (2015 EUD) for drug acquisition, administration and FN management were 
considered in the model. The outcomes were FN events avoided and incremental 
cost-effectiveness ratio (ICER) per FN event avoided. Results: PP with pegfilgrastim 
was associated with fewest FN events (calculated by combining FN risk with the 
efficacy of G-CSFs: 0.110, 0.100, 0.127 for TC, AC-T, FEC-D, respectively) followed by 
PP with lipegfilgrastim (0.160, 0.146, 0.186 for TC, AC-T, FEC-D, respectively) and PP 
